NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY
OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA,
JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS
ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER
OF SECURITIES IN ANY JURISDICTION.
22 March 2024
LungLife AI,
Inc.
(the
"Company" or "LungLife")
Admission of New
Shares
and
PDMR
Dealing
LungLife AI, Inc. (AIM:
LLAI), a developer of clinical diagnostic solutions
for the early detection of lung cancer,
announces that, further to the Company announcements on 4 March
2025, 5 March 2024 and 21 March 2024, 5,172,621 new shares of
common stock have been admitted to trading on AIM under the ticker
symbol LLA and ISIN USU5500L1128 in connection with the
Fundraising.
The Company also announces that it
has been notified of transactions in the Company's Common Shares by
directors in connection with the Fundraising, as detailed in the
Appendix to the announcement.
The Company's total issued share
capital now consists of 30,658,603 Common Shares of US$0.0001
each with one
voting right per Common Share. There
are no Common Shares held in treasury. The total number of voting
rights in the Company is therefore 30,658,603. This number may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the
Company.
Unless otherwise defined in this
announcement, capitalised terms used in this announcement shall
have the same meanings as defined in the Company's announcement of
4 March 2024.
For further
information please contact:
|
LungLife AI,
Inc.
|
www.lunglifeai.com
|
|
Paul Pagano, CEO
|
Via Walbrook PR
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser & Joint
Broker)
|
Tel: +44 (0)20 7597
5970
|
|
Virginia Bull / Cameron MacRitchie / Lydia
Zychowska
|
|
|
|
|
|
Goodbody Stockbrokers UC (Joint Broker)
Tom Nicholson / Cameron Duncan /
William Hall
|
Tel: +44 (0)20 3841
6202
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933
8780
|
|
Paul McManus / Alice Woodings /
Phillip Marriage
|
or LungLifeAI@walbrookpr.com
|
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the
Company's LungLB® test is designed to deliver additional
information to clinicians who are evaluating indeterminate lung
nodules. For more information visit
www.lunglifeai.com
APPENDIX
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1
|
Details of the person
discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Paul Pagano
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial
notification/amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
LungLife AI, Inc.
|
|
b)
|
LEI
|
549300VBVDIF0Y3OVI38
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Common shares of US$0.0001
each
ISIN: USU5500L1128
|
|
b)
|
Nature of the transaction
|
Participation in
Fundraising
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
35p
|
14,285
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
N/A
|
|
e)
|
Date of the transaction
|
22 March 2024
|
|
f)
|
Place of the transaction
|
Outside a Trading Venue
|
|
1
|
Details of the person
discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
David Anderson
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial
notification/amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
LungLife AI, Inc.
|
|
b)
|
LEI
|
549300VBVDIF0Y3OVI38
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Common shares of US$0.0001
each
ISIN: USU5500L1128
|
|
b)
|
Nature of the transaction
|
Participation in
Fundraising
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
35p
|
14,285
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
N/A
|
|
e)
|
Date of the transaction
|
22 March 2024
|
|
f)
|
Place of the transaction
|
Outside a Trading Venue
|
|
1
|
Details of the person
discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Gordon Roy Davis
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Chairman
|
|
b)
|
Initial
notification/amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
LungLife AI, Inc.
|
|
b)
|
LEI
|
549300VBVDIF0Y3OVI38
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Common shares of US$0.0001
each
ISIN: USU5500L1128
|
|
b)
|
Nature of the transaction
|
Participation in
Fundraising
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
35p
|
28,571
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
N/A
|
|
e)
|
Date of the transaction
|
22 March 2024
|
|
f)
|
Place of the transaction
|
Outside a Trading Venue
|
|
1
|
Details of the person
discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Andrew Boteler
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial
notification/amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
LungLife AI, Inc.
|
|
b)
|
LEI
|
549300VBVDIF0Y3OVI38
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Common shares of US$0.0001
each
ISIN: USU5500L1128
|
|
b)
|
Nature of the transaction
|
Participation in
Fundraising
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
35p
|
28,571
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
N/A
|
|
e)
|
Date of the transaction
|
22 March 2024
|
|
f)
|
Place of the transaction
|
Outside a Trading Venue
|
IMPORTANT
NOTICES
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND
THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR
PUBLICATION, RELEASE, TRANSMISSION, FORWARDING OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED
STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF
THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE
"UNITED STATES"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY
OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR
DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR
INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY
JURISDICTION.
The securities referred to herein have not been
and will not be registered under the US Securities Act of 1933, as
amended (the "Securities Act"), or with any securities regulatory
authority of any State or other jurisdiction of the United States,
and may not be offered, sold or transferred, directly or
indirectly, in or into the United States, or to or for the account
or benefit of US persons (as defined in Regulation S under the
Securities Act ("Regulation S")), except pursuant to an exemption
from, or in a transaction not subject to, the registration
requirements of the Securities Act and in compliance with the
securities laws of any State or any other jurisdiction of the
United States.